Marché mondial des cellules ovariennes de hamster chinois (CHO) – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse du marché et de la taille des cellules ovariennes de hamster chinois (CHO)

Sur le marché des cellules ovariennes de hamster chinois (CHO), les avancées ont révolutionné la production biopharmaceutique. Grâce à leur polyvalence, les cellules CHO offrent des avantages tels qu'un rendement accru et une meilleure qualité des protéines, ce qui favorise leur adoption généralisée dans la recherche biotechnologique et le développement de médicaments. Ce marché connaît une innovation continue, propulsant l'industrie biopharmaceutique vers l'avant. Alors que la demande de produits biologiques augmente, les cellules CHO restent essentielles, garantissant une production efficace et répondant aux besoins du marché pharmaceutique en pleine expansion.                                

La taille du marché mondial des cellules ovariennes de hamster chinois (CHO) était évaluée à 384 141,81 milliers USD en 2023 et devrait atteindre 737 784,42 milliers USD d'ici 2031, avec un TCAC de 8,5 % au cours de la période de prévision 2024 à 2031. Cela indique la valeur marchande. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Chinese hamster ovary (CHO) cells are a commonly used cell line in biotechnology and pharmaceutical research. These cells, derived from the ovaries of the Chinese hamster, offer advantages such as rapid growth, easy cultivation, and the ability to produce complex proteins. CHO cells are extensively utilized in the production of therapeutic proteins, vaccines, and monoclonal antibodies due to their capability for high-yield protein expression and post-translational modifications.           

Chinese Hamster Ovary (CHO) Cells Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The global rise in chronic diseases such as cancer, autoimmune disorders, and infectious diseases is fueling demand for biopharmaceuticals. As these conditions become more prevalent, there is a growing need for effective treatments, leading to increased production of biologics. CHO cells play a crucial role in this process, being widely used for biopharmaceutical manufacturing due to their ability to produce complex proteins. This trend propels the growth of the CHO cell market worldwide.

• Growing Biopharmaceutical Industry

The surging demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and recombinant proteins, is fueling the expansion of the CHO cell market. CHO cells excel in producing these biologics due to their capacity for post-translational modifications and high protein expression levels. For instance, the production of monoclonal antibodies such as rituximab and trastuzumab heavily relies on CHO cells, highlighting their pivotal role in meeting the escalating demand for biopharmaceuticals.

Opportunities

• Advancements in Cell Line Engineering Technologies

Advancements in cell line engineering, such as CRISPR/Cas9, are revolutionizing CHO cell development. Through precisely editing the genome, researchers can enhance productivity and stability, key factors in biopharmaceutical production. For instance, targeted modifications can optimize protein expression or streamline metabolic pathways, resulting in higher yields and better product quality. These innovations are driving the expansion of the Chinese hamster ovary cells market by offering more efficient and reliable production platforms.

• Expansion of Contract Development and Manufacturing Organizations (CDMOs)

The outsourcing trend in biopharmaceutical manufacturing to contract development and manufacturing organizations (CDMOs) is escalating, fueled by the imperative for adaptable production capabilities and specialized expertise. Numerous CDMOs rely on CHO cell-based systems for bioproduction, heightening the demand for CHO cell culture products and services. This surge underscores the pivotal role of CDMOs in meeting the burgeoning demands of the biopharmaceutical industry while leveraging CHO cell technology for efficient production. 

Restraints/Challenges

• Supply Chain Vulnerabilities

The CHO cell market grapples with susceptibility to supply chain disruptions due to its dependence on a limited number of suppliers for cell lines and culture media. Such vulnerabilities pose significant risks to production schedules and product availability, potentially leading to delays and shortages in the market.

• High Cost of Production

The high costs of producing, maintaining, and scaling up CHO cell cultures pose significant barriers to adoption, particularly for smaller biotech firms and academic institutions with constrained budgets. These expenses encompass the procurement of Chinese hamster ovary cell line, culture media, specialized equipment, and skilled personnel, making it challenging for organizations with limited resources to engage in biopharmaceutical research and production using CHO cells. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In July 2023, Merck KGaA unveiled plans for expanding its Lenexa, Kansas facility, adding 9,100 square meters of laboratory space and enhancing production capacity for cell culture media. This strategic move aligns with the company's goal to bolster its supply chain, catering to the escalating demand for Chinese hamster ovary cell culture platforms
• In February 2023, the European Investment Bank (EIB) finalized an €18 million deal with Estonia-based biotech firm, Icosagen AS. The funding will bolster Icosagen's production facility and advance its research & development technology platforms, reinforcing its position as a frontrunner in biotechnology innovation
• In February 2022, Sartorius AG completed the acquisition of Novasep's business, augmenting its chromatography portfolio. This addition includes systems tailored for small biomolecules such as oligonucleotides, peptides, and insulin, as well as innovative platforms for continuous biopharmaceutical production, bolstering Sartorius' offerings in the biopharma sector
• In January 2021, Pfizer announced a USD 120 million investment in biotechnology innovation through the Pfizer Breakthrough Growth Initiative (PBGI). This initiative, part of a larger commitment of up to USD 500 million, aims to support biotech startups with funding and access to Pfizer's scientific expertise, fostering breakthroughs in the field

Chinese Hamster Ovary (CHO) Cells Market Scope

The market is segmented on the basis of type, system, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Services
• Product

 System

• Metabolic Selection System
• Antibiotic Selection System
• Others

 Application

• Biologics
• Medical Research

 End User

• Biopharmaceutical Companies
• Biotechnology Companies
• Clinical Development and Manufacturing Organizations
• Clinical Research Organizations
• Academic Institutes and Research Organizations
• Others

 Distribution Channel

• Direct Tenders
• Retail Sales
• Others

Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, system, application, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the Chinese hamster ovary (CHO) cells market, sustained by key market players and the region's status as the largest consumer market with a high GDP. The concentration of industry leaders further solidifies its position as a frontrunner in CHO cell technologies.

Asia-Pacific is expected to show significant growth in the Chinese hamster ovary (CHO) cells market, driven by China's dominance in the region. Mass production of CHO cells-based products, coupled with rising demand from emerging markets and expansion initiatives, underpins this growth trajectory.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Croissance des infrastructures de santé Base installée et pénétration des nouvelles technologies

Le marché vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les biens d'équipement, la base installée de différents types de produits pour le marché, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché. Les données sont disponibles pour la période historique 2016-2021.

Analyse du paysage concurrentiel et des parts de marché des cellules ovariennes de hamster chinois (CHO)

Le paysage concurrentiel du marché fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs opérant sur le marché sont :

• Thermo Fisher Scientific Inc. (États-Unis)
• AcceGen (États-Unis)
• RayBiotech Life, Inc. (États-Unis)
• CLS Cell Lines Service GmbH (Allemagne)
• BPS Bioscience, Inc. (États-Unis)
• GenTarget Inc. (États-Unis)
• Merck KGaA (Allemagne)
• Promega Corporation (États-Unis)
• Abeomics (États-Unis)
• Matériaux biologiques appliqués inc. (abm) (Canada)
• ATCC (États-Unis)
• Sartorius AG (Allemagne)
• Lonza (Suisse)
• Horizon Discovery Ltd. (Royaume-Uni)
• Cytiva (États-Unis)
• GTP Bioways (États-Unis)
• Curia Global, Inc. (États-Unis)

SKU-52373